Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited ( (HK:2181) ) just unveiled an announcement.
Mabpharm Limited announced its interim financial results for the first half of 2025, reporting a significant increase in revenue and gross profit compared to the same period in 2024. The company achieved a profit before tax of RMB 2,898,000, marking a substantial turnaround from the previous year’s loss, indicating improved operational efficiency and market performance.
The most recent analyst rating on (HK:2181) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Mabpharm Limited stock, see the HK:2181 Stock Forecast page.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It is listed on the Stock Exchange of Hong Kong and focuses on the development and commercialization of innovative drugs.
Average Trading Volume: 546,558
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.18B
See more insights into 2181 stock on TipRanks’ Stock Analysis page.